{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:34:40Z","timestamp":1763037280367},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00108-019-0573-z","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T09:03:00Z","timestamp":1552294980000},"page":"440-449","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Membran\u00f6se Glomerulonephritis"],"prefix":"10.1007","volume":"60","author":[{"given":"Rolf A. K.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"573_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech AP, Hofstra JM, Brenchley PE et al (2014) Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9:1386\u20131392","journal-title":"Clin J Am Soc Nephrol"},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH, Bonegio RG, Lambeau G et al (2009) M\u2011type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N\u00a0Engl J Med 361:11\u201321","journal-title":"N Engl J Med"},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/ASN.2005010028","volume":"6","author":"D Cattran","year":"2005","unstructured":"Cattran D (2005) Management of membranous nephropathy: When and what for treatment. J\u00a0Am Soc Nephrol 6:1188\u20131194","journal-title":"J Am Soc Nephrol"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG (2017) Primary membranous Nephropathy. Clin J Am Soc Nephrol 12:983\u2013997","journal-title":"Clin J Am Soc Nephrol"},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","volume":"421","author":"C D\u00e4hnrich","year":"2013","unstructured":"D\u00e4hnrich C, Komorowski L, Probst C et al (2013) Development of a\u00a0standardized ELISA for the determination of autoantibodies against human M\u2011type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421:213\u2013218","journal-title":"Clin Chim Acta"},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E et al (2017) Rituximab for severe membranous Nephropathy: A 6\u2011month trial with extended follow-up. J\u00a0Am Soc Nephrol 28:348\u2013358","journal-title":"J Am Soc Nephrol"},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","volume":"346","author":"H Debiec","year":"2002","unstructured":"Debiec H, Guigonis V, Mougenot B et al (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N\u00a0Engl J Med 346:2053\u20132060","journal-title":"N Engl J Med"},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS Vriese De","year":"2016","unstructured":"De Vriese AS, Glassock RJ, Nath KA et al (2016) A proposal for a\u00a0serology-based approach to membranous Nephropathy. J\u00a0Am Soc Nephrol 28:421\u2013430","journal-title":"J Am Soc Nephrol"},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A et\u00a0al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179\u2013184","journal-title":"Science"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM et\u00a0al (2013) Immunosuppression for progressive membranous nephropathy: A\u00a0UK randomised controlled trial. Lancet 381:744\u2013751","journal-title":"Lancet"},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","volume":"28","author":"E Hoxha","year":"2017","unstructured":"Hoxha E, Beck LH Jr, Wiech T et al (2017) An indirect Immunofluorescence method facilitates detection of Thrombospondin type 1 domain-containing 7A-specific antibodies in membranous Nephropathy. J\u00a0Am Soc Nephrol 28:520\u2013531","journal-title":"J Am Soc Nephrol"},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2215\/CJN.03850414","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha E, Harendza S, Pinnschmidt H et al (2014) M\u2011type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9:1883\u20131889","journal-title":"Clin J Am Soc Nephrol"},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","volume":"26","author":"E Hoxha","year":"2011","unstructured":"Hoxha E, Harendza S, Zahner G et al (2011) An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526\u20132532","journal-title":"Nephrol Dial Transplant"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","volume":"82","author":"E Hoxha","year":"2012","unstructured":"Hoxha E, Knei\u00dfler U, Stege G et al (2012) Enhanced expression of the M\u2011type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82:797\u2013780","journal-title":"Kidney Int"},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","volume":"25","author":"E Hoxha","year":"2014","unstructured":"Hoxha E, Thiele I, Zahner G et\u00a0al (2014) Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J\u00a0Am Soc Nephrol 25:1357\u20131366","journal-title":"J Am Soc Nephrol"},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00424-017-2000-4","volume":"469","author":"E Hoxha","year":"2017","unstructured":"Hoxha E, von Haxthausen F, Wiech T et al (2017) Membranous nephropathy-one morphologic pattern with different diseases. Pflugers Arch 469:989\u2013996","journal-title":"Pflugers Arch"},{"key":"573_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","volume":"374","author":"E Hoxha","year":"2016","unstructured":"Hoxha E, Wiech T, Stahl PR et al (2016) A mechanism for cancer-associated membranous Nephropathy. N\u00a0Engl J Med 374:1995\u20131996","journal-title":"N Engl J Med"},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","volume":"83","author":"D Kanigicherla","year":"2013","unstructured":"Kanigicherla D, Gummadova J, McKenzie EA et al (2013) Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a\u00a0prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83:940\u2013948","journal-title":"Kidney Int"},{"issue":"18","key":"573_CR19","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","volume":"79","author":"D Kerjaschki","year":"1982","unstructured":"Kerjaschki D, Farquhar MG (1982) The pathogenic antigen of Heymann nephritis is a\u00a0membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 79(18):5557\u20135561. \n                    https:\/\/doi.org\/10.1073\/pnas.79.18.5557","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"573_CR20","first-page":"377","volume":"29","author":"M Mahmud","year":"2018","unstructured":"Mahmud M, Pinnschmidt HO, Reinhard L et\u00a0al (2018) Phospholipase A2 Receptor 1 antibody levels at the time of diagnosis determine renal outcome in patients with membranous nephropathy. J\u00a0Am Soc Nephrol 29:377","journal-title":"J Am Soc Nephrol"},{"key":"573_CR21","first-page":"268","volume":"20","author":"C Ponticelli","year":"2007","unstructured":"Ponticelli C (2007) Membranous Nephropathy. J\u00a0Nephrol 20:268\u2013287","journal-title":"J Nephrol"},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Chiurchiu C, Abbate M et\u00a0al (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360:923\u2013924","journal-title":"Lancet"},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A et\u00a0al (2012) Rituximab in idiopathic membranous nephropathy. J\u00a0Am Soc Nephrol 23:1416\u20131425","journal-title":"J Am Soc Nephrol"},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1172\/JCI109837","volume":"66","author":"DJ Salant","year":"1980","unstructured":"Salant DJ, Darby C, Couser WG (1980) Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals. J\u00a0Clin Invest 66:71\u201381","journal-title":"J Clin Invest"},{"key":"573_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1003066","volume":"363","author":"R Stahl","year":"2010","unstructured":"Stahl R, Hoxha E, Fechner K (2010) PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N\u00a0Engl J Med 363:496\u2013498","journal-title":"N Engl J Med"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","volume":"28","author":"B Svobodova","year":"2013","unstructured":"Svobodova B, Honsova E, Ronco P et al (2013) Kidney biopsy is a\u00a0sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 28:1839\u20131844","journal-title":"Nephrol Dial Transplant"},{"key":"573_CR27","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N\u00a0Engl J Med 371:2277\u20132287","journal-title":"N Engl J Med"},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1172\/JCI85265","volume":"126","author":"NM Tomas","year":"2016","unstructured":"Tomas NM, Hoxha E, Reinicke AT et al (2016) Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J\u00a0Clin Invest 126:2519\u20132532","journal-title":"J Clin Invest"},{"key":"573_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03035","author":"F Haxthausen Von","year":"2018","unstructured":"Von Haxthausen F, Reinhard L, Pinnschmidt HO et al (2018) Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy. Front Immunol 9. \n                    https:\/\/doi.org\/10.3389\/fimmu.2018.03035","journal-title":"Front Immunol"},{"issue":"2","key":"573_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/j.ajkd.2018.09.003","volume":"73","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Gong T, Rennke HG et\u00a0al (2019) Duodenal Schwannoma as a\u00a0rare association with membranous Nephropathy: A case report. Am J Kidney Dis 73(2):278\u2013280. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2018.09.003","journal-title":"Am J Kidney Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0573-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0573-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0573-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:25:41Z","timestamp":1583799941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0573-z"}},"subtitle":["Ein Beispiel f\u00fcr individualisierte Medizin in der Nephrologie"],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0573-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"11 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Arbeiten von R.A.K.\u00a0Stahl und E.\u00a0Hoxha werden von der Deutschen Forschungsgemeinschaft im Rahmen des Sonderforschungsbereichs SFB\u00a01192 (Projekte\u00a0B1, B2 und C1) unterst\u00fctzt. E.\u00a0Hoxha wird von der Else Kr\u00f6ner-Fresenius-Stiftung unterst\u00fctzt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}